HE3235 Inhibits Growth of Castration-Resistant Prostate Cancer

Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy. However, most patients eventually develop castration-resistant CaP (CRPC) for which highly effective therapies are limited. We explored the efficacy of a novel agent, HE3235, in inhibiting growth of CRPC in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Koreckij, Theodore D, Trauger, Richard J, Montgomery, Robert Bruce, Pitts, Tiffany EM, Coleman, Ilsa, Nguyen, Holly, Reading, Chris L, Nelson, Peter S, Vessella, Robert L, Corey, Eva
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Neoplasia Press Inc. 2009
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2767223/
https://ncbi.nlm.nih.gov/pubmed/19881957
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller